Revolutionary Alzheimer's Drug Reverses Memory Loss in Mice

Breakthrough Discovery Challenges Century-Old Beliefs

For over a century, Alzheimer's disease has been viewed as an irreversible condition that inevitably progresses toward cognitive decline and memory loss. Alzheimer's has long been considered irreversible, but new research challenges that assumption. For more than 100 years, Alzheimer's disease (AD) has been widely viewed as a condition that cannot be undone. Recent groundbreaking research from multiple scientific teams has shattered this long-held belief, demonstrating that advanced Alzheimer's disease can not only be halted but completely reversed in animal models.

The most compelling evidence comes from researchers at Case Western Reserve University and University Hospitals, who showed that severe drops in the brain's energy supply help drive the disease—and restoring that balance can reverse damage, even in advanced cases. Even more striking, restoring NAD+ balance after the disease was already advanced allowed the brain to repair damage and fully restore cognitive function. Their compound, P7C3-A20, achieved something unprecedented: Both mouse models showed complete recovery of cognitive function.

Simultaneously, researchers at the University of Barcelona developed FLAV-27, an entirely different approach that targets the brain's epigenetic machinery. FLAV-27, a first-in-class brain-penetrant G9a inhibitor, reverses cognitive deficits and pathology in Alzheimer disease models by targeting S-adenosyl-l-methionine-competitive methylation. In mouse models of both late-onset AD (SAMP8) and early-onset AD (5xFAD), FLAV-27 rescues memory performance, social behavior, and synaptic structure.

Two Revolutionary Approaches to Brain Repair

The energy restoration approach focuses on a critical cellular molecule called NAD+, which powers essential brain functions. By 6 months, however, when pathology and cognitive deficits are apparent, 5xFAD mice exhibited a 30% reduction in brain NAD+/NADH progressing to 45% by 12 months. In advanced disease amyloid-driven 5xFAD mice, treatment with P7C3-A20, which restores nicotinamide adenine dinucleotide (NAD+) homeostasis, reverses tau phosphorylation, blood-brain barrier deterioration, oxidative stress, DNA damage, and neuroinflammation and enhances hippocampal neurogenesis and synaptic plasticity, resulting in full cognitive recovery.

The epigenetic approach takes a fundamentally different strategy. While current drugs for Alzheimer's mostly focus on removing amyloid-beta plaques associated with the disease, the new compound takes a fundamentally different approach, instead targeting a specific enzyme to therapeutically reprogram the epigenome of neurons. FLAV-27 is the first inhibitor of its kind to target an enzyme called euchromatic histone-lysine N-methyltransferase 2 (EHMT2), also known as G9a. G9a is involved in epigenetic regulation within the brain, and can silence genes important for key tasks such as brain cell development, synaptic plasticity, and memory processing.

Both treatments demonstrated remarkable effectiveness across multiple measures. These included restored blood-brain barrier integrity, reduced oxidative stress and DNA damage, decreased neuroinflammation, and enhanced synaptic plasticity. The treatment restored cognitive function and showed biological improvements. These included restored blood-brain barrier integrity, reduced oxidative stress and DNA damage, decreased neuroinflammation, and enhanced synaptic plasticity.

Beyond Current Treatment Limitations

Today's approved Alzheimer's drugs, including lecanemab and donanemab, represent important advances but have significant limitations. Monoclonal antibody drugs such as lecanemab and donanemab, which target amyloid-beta proteins, help somewhat to slow the progression of the disease when treatment is started early, but there is still no proven way to reverse cognitive decline from Alzheimer's in humans. Bellver-Sanchis and her colleagues note that while monoclonal antibodies represent a genuine breakthrough in Alzheimer's treatment, lecanemab and donanemab only slow cognitive decline by around 30 percent and address only part of the condition's pathology.

These new approaches offer hope for something far more ambitious than slowing decline. "The key takeaway is a message of hope—the effects of Alzheimer's disease may not be inevitably permanent," Pieper said. "This new therapeutic approach to recovery needs to be moved into carefully designed human clinical trials to determine whether the efficacy seen in animal models translates to human patients," Pieper said.

The research also revealed potential biomarkers that could revolutionize treatment monitoring. This recovery was also reflected in blood tests, which showed normalized levels of phosphorylated tau 217, a recently approved clinical biomarker used to diagnose Alzheimer's in people. These findings provided strong evidence of disease reversal and highlighted a potential biomarker for future human trials.

A New Era of Alzheimer's Research

These discoveries represent more than incremental progress—they suggest a paradigm shift in how we understand and treat neurodegenerative diseases. However, the results of this study challenge that assumption. The research suggests that Alzheimer's disease may not be an inevitably progressive condition and that under certain conditions